2023
Total and treatment-related costs of care associated with in patients with metastatic renal cell carcinoma receiving targeted or immune therapy.
Rahman S, Long J, Westvold S, Wheeler S, Spees L, Leapman M, Hurwitz M, McManus H, Gross C, Dinan M. Total and treatment-related costs of care associated with in patients with metastatic renal cell carcinoma receiving targeted or immune therapy. JCO Oncology Practice 2023, 19: 28-28. DOI: 10.1200/op.2023.19.11_suppl.28.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaOral anticancer agentsInitial treatmentRetrospective cohort studyUse of immunotherapyYear of diagnosisRenal cell carcinomaDirect treatment costsMean Medicare paymentsMedicare paymentsMedicare Part DInitial therapyCohort studyMetastatic diagnosisCell carcinomaCombination therapyImmunotherapyMedicare beneficiariesPatientsAge 65Disease controlOlder ageStudy periodTherapyDiagnosis
2013
Longitudinal trends in costs for palliative radiation for metastatic prostate cancer.
Robinson T, Dinan M, Li Y, Lee R, Reed S. Longitudinal trends in costs for palliative radiation for metastatic prostate cancer. Journal Of Clinical Oncology 2013, 31: 6554-6554. DOI: 10.1200/jco.2013.31.15_suppl.6554.Peer-Reviewed Original ResearchPalliative radiation therapyMetastatic prostate cancerProstate cancerRadiation therapyBony metastasesInclusion criteriaOutpatient facilitiesMedicare paymentsDistant metastatic diseaseTime of diagnosisPalliative radiation treatmentSEER-Medicare dataTreatment claimsStudy inclusion criteriaProstate cancer metastasisHealth care costsTotal Medicare paymentsAverage Medicare paymentsHealth care expendituresCarrier claimsPalliative radiationMetastatic diseasePalliative treatmentMedian ageMedian time